[代谢性骨病：2024年的新动向]。

Q4 Medicine

Revue medicale suisse Pub Date : 2025-01-15 DOI:10.53738/REVMED.2025.21.900-1.45

Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy

{"title":"[代谢性骨病：2024年的新动向]。","authors":"Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy","doi":"10.53738/REVMED.2025.21.900-1.45","DOIUrl":null,"url":null,"abstract":"The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 900-1","pages":"45-48"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Metabolic bone diseases : what's new in 2024].\",\"authors\":\"Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy\",\"doi\":\"10.53738/REVMED.2025.21.900-1.45\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"21 900-1\",\"pages\":\"45-48\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2025.21.900-1.45\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2025.21.900-1.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

股骨骨折的流行病学正在发生变化，更多的股骨骨干骨折与老年人的高风险体育锻炼有关。在怀孕期间为母亲的健康服用维生素D对孩子也有好处。唑来膦酸是最有效的二膦酸盐。髋部骨折患者住院期间应服用。Denosumab不应用于严重肾功能衰竭患者。当停用denosumab时，为了控制反弹效应，需要将骨吸收标志物保持在非常低的水平，以尽可能地维持增加的骨量。最后，在治疗罕见骨病方面继续取得进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Metabolic bone diseases : what's new in 2024].

The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revue medicale suisse Medicine-Medicine (all)

CiteScore

0.60

自引率

0.00%

发文量

1210

期刊介绍： Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.